Recommendation On Antifungal Therapy In Covid Associated Muc
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Since the onset of the Covid-19 pandemic, there have been multiple reports across the country of the very high incidence of mucormycosis among Covid-19 patients, especially in those who are diabetic and have received steroids.

Covid Associated Mucormycosis (CAM) has been associated with high morbidity and mortality, exorbitant treatment costs and has led to a shortage of antifungal drugs.

Fungal Infection Study Forum (FISF) releases recommendation on antifungal therapy in Covid associated mucormycosis when antifungal drug availability is limited:

• Antifungal prophylaxis is not recommended
• Start calculated dose of amphotericin B from first day, avoid dose
escalation
• Fluconazole, voriconazole, echinocandins (caspofungin,
anidulafungin, micafungin) or 5 flurocytosine is not active against
mucormycosis
• Combination of antifungal therapy is generally not recommended

To know more, Checkout the below presentation:

Source:
Fungal Infection Study Forum
N●●●a J●●a and 10 others like this2 shares
Like
Comment
Share